MGMT and glioblastoma: The counterpart of this trial, CheckMate 548 (NCT02667587), in which similar treatments were tested in MGMT-methylated glioblastoma patients (a phase II trial with n = ~160 per arm), showed no increase in progression-free survival (PFS).